Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Cheuk-Man Yu,
Mr Jean-Claude Daubert,
By Cheuk-Man Yu, FESC (Hong Kong, Hong Kong SAR, People's Republic of China)View Discussant report
Open the PresentationWatch the Webcast
List of Authors: 1 Cheuk-man Yu, MD, FRCP, FACC; 1 Fang Fang, BM, PhD; 1 Xiu-xia Luo, BM; 2 Qing Zhang, BM, PhD; 3 Hussin Azlan, MD, FHRS, FACC; 3 Omar Razali, MD, FHRS, FACC1 Division of Cardiology, Department of Medicine and Therapeutics; Institute of Vascular Medicine; Institute of Innovative Medicine; Heart Education And Research Training (HEART) Center; and Li Ka Shing Institute of Health Sciences; Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong2 Department of Cardiology, West China Hospital, Sichuan University, China3 Department of Cardiology, National Heart Institute, Kuala Lumpur, Malaysia
ObjectivesWe reported the results of long-term follow-up of Pacing to Avoid Cardiac Enlargement (PACE) trial, a prospective, double-blinded, randomized, multicenter study that confirmed the superiority of biventricular (BiV) pacing to right ventricular apical (RVA) pacing in prevention of left ventricular (LV) adverse remodeling and deterioration of systolic function. MethodsPatients with bradycardia and preserved LV ejection fraction (LVEF) were randomized to receive RVA (n=88) or BiV pacing (n=89). Co-primary end-points were LV end-systolic volume (LVESV) and LVEF measured by echocardiography. ResultsThere were 149 patients who had extended followed up with a mean duration of 4.8±1.5 years. The primary end-point analyses were performed in 146 patients (74 in RVA group and 72 in BiV group). In the RVA pacing group, the LVEF decreased while the LVESV increased progressively at follow-up, but remained unchanged in the BiV pacing group. Therefore, the differences in LVEF between the RVA and BiV groups were -6.3%, -9.2% and -10.7% at 1-year, 2-year and long-term follow-up, respectively (all P<0.001). The corresponding differences in LVESV were +7.4 ml, +9.9 ml and +13.1 ml, respectively (all P<0.001). The deleterious effects of RVA pacing consistently occurred in all the pre-defined subgroups. Furthermore, patients with RVA pacing had a significantly higher prevalence of heart failure hospitalization than the BiV group (23.9% Vs 14.6%, Log-rank 2=7.55, P=0.006). ConclusionLV adverse remodeling and deterioration of systolic function continued at long-term follow-up in patients with RVA pacing, which were prevented by the use of BiV pacing. Also, heart failure hospitalization was more prevalent in the RVA pacing group.
By Jean-Claude Daubert, FESC (Rennes, France)See Presenter abstractOpen the presentationWatch the Webcast
Clinical Trial Update Hot Line: Interventions and drug therapy